Retrieve available abstracts of 341 articles: HTML format
Single Articles
June 2025
VIT F, Bittolo T, Zucchetto A, Papotti R, et al Measurement of Immunoglobulin Intraclonal diversification refines the clinical
impact of IGHV mutational status in chronic lymphocytic leukemia.
Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02650. PubMedAbstract available
IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al Impact of myelodysplasia-related gene mutations and residual mutations at
remission in venetoclax/azacitidine for AML.
Leukemia. 2025;39:1362-1367. PubMedAbstract available
BUCKLEY M, Yeung DT, White DL, Eadie LN, et al T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and
emerging targeted treatments.
Leukemia. 2025;39:1294-1310. PubMedAbstract available
VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al CLL cell-derived exosomes alter the immune and hematopoietic systems.
Leukemia. 2025;39:1380-1394. PubMedAbstract available
May 2025
ZHANG Y, Feng Z, Du J, Liu H, et al High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in
first complete remission: a randomized controlled trial.
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655. PubMedAbstract available
BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.
Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653. PubMed
DEMBITZ V, James SC, Gallipoli P Targeting lipid metabolism in acute myeloid leukemia: biological insights and
therapeutic opportunities.
Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645. PubMedAbstract available
AUER F, Morcos MNF, Sipola M, Akhtar I, et al Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay
in vivo.
Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626. PubMedAbstract available
KUHN MWM, Pemmaraju N, Heidel FH The evolving landscape of epigenetic target molecules and therapies in myeloid
cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639. PubMedAbstract available
NGUYEN NTK, Yao H, Hosokawa K, Esaki Y, et al Acute myeloid leukemia stem cells remodel the bone marrow niche via
TGF-beta-activated Alcam(+) bone lining cells, creating a self-sustaining
environment.
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02640. PubMed
WANG'ONDU RW, Ashcraft E, Chang TC, Roberts KG, et al Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood
B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633. PubMedAbstract available
BATALLER A, Goulart HE, Issa GC, DiNardo CD, et al Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A
rearrangements.
Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634. PubMedAbstract available
IZUMI S, Ohtani K, Matsumoto M, Shibata S, et al Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain
in MLL-rearranged leukemia.
Leukemia. 2025 May 8. doi: 10.1038/s41375-025-02638. PubMedAbstract available
NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis
in FLT3-ITD acute myeloid leukemia.
Leukemia. 2025 May 5. doi: 10.1038/s41375-025-02637. PubMed
LAUSEKER M, Hoffmann VS, Pfirrmann M Prognostic scoring systems in chronic myeloid leukaemia.
Leukemia. 2025;39:1046-1052. PubMedAbstract available
TAKAMORI H, Huang YJ, Fukushima H, Yokoyama K, et al Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal
changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in
the fibrotic transformation.
Leukemia. 2025;39:1218-1227. PubMedAbstract available
April 2025
HASAN MK, Widhopf Ii GF, Ghia EM, Kipps TJ, et al Wnt5a induces ROR1 dependent NF-kappaB activation to enhance MMP-9 expression and
invasiveness in chronic lymphocytic leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616. PubMedAbstract available
MECKLENBRAUCK R, Borchert N, Gabdoulline R, Poll P, et al Prognostic impact of clonal representation of myelodysplasia-related gene
mutations in acute myeloid leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622. PubMed
KRIZKOVA J, Polivkova V, Laznicka A, Curik N, et al Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young
adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic
leukemia.
Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609. PubMedAbstract available
GHANI F, Zubair AC Possible impacts of cosmic radiation on leukemia development during human deep
space exploration.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02624. PubMedAbstract available
THORVALDSDOTTIR B, Mansouri L, Sutton LA, Nadeu F, et al ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM
mutations is an adverse-prognostic biomarker.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02615. PubMedAbstract available
ZHOU T, Short NJ, Jain N, Patel KP, et al Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic
leukemia/lymphoma (B-ALL): insights from a decade of national data.
Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588. PubMed
WU JF, Feliciano EJG, Singh A, Tremblay D, et al National cancer system metrics and leukemia outcomes: an analysis of global data
for pediatric and adult patients.
Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02598. PubMed
SHIMA Y, Yamagata K, Kuroki Y, Sasaki K, et al Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.
Leukemia. 2025 Apr 22. doi: 10.1038/s41375-025-02607. PubMedAbstract available
ASHAYE A, Shi L, Aldoss I, Montesinos P, et al Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic
leukemia patients treated with ponatinib or imatinib: results from the PhALLCON
trial.
Leukemia. 2025 Apr 16. doi: 10.1038/s41375-025-02608. PubMedAbstract available
XU Y, Mou J, Wang Y, Zhou W, et al Correction: Regulatory T cells promote the stemness of leukemia stem cells
through IL10 cytokine-related signaling pathway.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02618. PubMed
NIEDERMAYER A, Stursberg J, Bergmann AK, Zimmermann M, et al Remission induction in refractory, drug resistant pediatric
PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02591. PubMed
DECHOW A, Timonen S, Ianevski A, Jiang Q, et al Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic
leukemia.
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577. PubMedAbstract available
HSU CJ, Schraw JM, Desrosiers TA, Janitz AE, et al All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased
incidence rates in children with Down syndrome.
Leukemia. 2025 Apr 11. doi: 10.1038/s41375-025-02602. PubMed
XING C, Zhang H, Zheng M, Lu Q, et al Fabp4 is essential for the maintenance of leukemia stem cells while sparing
hematopoietic stem cells.
Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02568. PubMed
CORTES JE, Lang F, Rea D, Hochhaus A, et al Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with
chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final
results.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592. PubMedAbstract available
KAYA F, Bewicke-Copley F, Miettinen JJ, Casado P, et al DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential
leukemia genes.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02593. PubMedAbstract available
HOCHHAUS A, Kim DW, Cortes JE, Sasaki K, et al Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase
without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final
results.
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578. PubMedAbstract available
PAGANO L, Maschmeyer G, Lamoth F, Blennow O, et al Primary antifungal prophylaxis in hematological malignancies. Updated clinical
practice guidelines by the European Conference on Infections in Leukemia (ECIL).
Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586. PubMedAbstract available
REINHARDT C, Ochsenbein AF Immune checkpoints regulate acute myeloid leukemia stem cells.
Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566. PubMedAbstract available
LI R, Wu X, Xue K, Wu S, et al CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the
maintenance of FLT3-ITD acute myeloid leukemia.
Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02589. PubMedAbstract available
BUSSOT L, Poulain S, Nudel Ortmans M, Davi F, et al Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic
lymphocytic leukemia : a real-world multicentric study.
Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02555. PubMed
HUANG J, Xie J, Wang Y, Sheng M, et al STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated
hematopoietic stem/progenitor cells.
Leukemia. 2025;39:929-941. PubMedAbstract available
SHI C, Tian Z, Yan J, Zhang M, et al Immunotherapy targeting a leader sequence cathepsin G-derived peptide.
Leukemia. 2025;39:888-898. PubMedAbstract available
March 2025
AYYADEVARA VSSA, Wertheim G, Gaur S, Chukinas JA, et al DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute
lymphoblastic leukemia cells sensitive to BCL2 inhibition.
Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02575. PubMedAbstract available
CHARLES CANO F, Kloos A, Hebalkar RY, Plenge T, et al XPO1-dependency of DEK::NUP214 leukemia.
Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02570. PubMedAbstract available
JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al Implementation of standard of care CAR-T-cell treatment for patients with
aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573. PubMed
STOLTZE U, Junk SV, Byrjalsen A, Cave H, et al Overt and covert genetic causes of pediatric acute lymphoblastic leukemia.
Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02535. PubMedAbstract available
GEYER J, Opoku KB, Lin J, Ramkissoon L, et al Real-time genomic characterization of pediatric acute leukemia using adaptive
sampling.
Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02565. PubMedAbstract available
COLE FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, et al Preclinical characterization of the anti-leukemia activity of the CD123
antibody-drug conjugate, pivekimab sunirine (IMGN632).
Leukemia. 2025 Mar 21. doi: 10.1038/s41375-025-02571. PubMed
ROMPIETTI C, Adamo FM, Sorcini D, De Falco F, et al Bcor loss promotes Richter transformation of chronic lymphocytic leukemia
associated with Notch1 activation in mice.
Leukemia. 2025 Mar 20. doi: 10.1038/s41375-025-02557. PubMedAbstract available
SHAH BD, Cassaday RD, Park JH, Houot R, et al Three-year analysis of adult patients with relapsed or refractory B-cell acute
lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Leukemia. 2025 Mar 19. doi: 10.1038/s41375-025-02532. PubMedAbstract available
SPERB N, Maksakova IA, Escano L, Abraham L, et al The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid
leukemia through mitochondrial activation.
Leukemia. 2025 Mar 17. doi: 10.1038/s41375-025-02558. PubMedAbstract available
WANG H, Suo S, Li D, Li J, et al Comparison of subcutaneous injection versus intravenous infusion of cytarabine
for induction therapy in adult acute myeloid leukemia.
Leukemia. 2025 Mar 12. doi: 10.1038/s41375-025-02556. PubMed
KLEPZIG H, Herling M, Pflug N, Braun T, et al Models for T-large granular lymphocytic leukemia: how to mimic the cellular
interplays in malignant autoimmunity.
Leukemia. 2025 Mar 7. doi: 10.1038/s41375-025-02553. PubMedAbstract available
MILLOT F, Ampatzidou M, Moulik NR, Tewari S, et al Management of children and adolescents with chronic myeloid leukemia in chronic
phase: International pediatric chronic myeloid leukemia expert panel
recommendations.
Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02543. PubMedAbstract available
LIPTON JH, Rea D Living, not just surviving, with chronic myeloid leukemia - quality of life to
the front of the line.
Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02548. PubMed
BRUNMEIR R, Ying L, Yan J, Hee YT, et al EZH2 modulates mRNA splicing and exerts part of its oncogenic function through
repression of splicing factors in CML.
Leukemia. 2025;39:650-662. PubMedAbstract available
February 2025
REUVEKAMP T, Ngai LL, den Hartog D, Carbaat-Ham J, et al CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid
leukemia patients treated non-intensively with hypomethylating agents.
Leukemia. 2025 Feb 27. doi: 10.1038/s41375-025-02539. PubMed
DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al Long term results of venetoclax combined with FLAG-IDA induction and
consolidation for newly diagnosed and relapsed or refractory acute myeloid
leukemia.
Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02531. PubMedAbstract available
GIUDICE V, Selleri C How fast does leukemia progress?
Leukemia. 2025 Feb 24. doi: 10.1038/s41375-025-02536. PubMed
MINAMI M, Sakoda T, Kawano G, Kochi Y, et al Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic
structure of PML::RARalpha.
Leukemia. 2025 Feb 20. doi: 10.1038/s41375-025-02530. PubMedAbstract available
HORMANN FM, Rudd SG Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and
molecular mode-of-action.
Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02529. PubMedAbstract available
ABEDIN SM, Guru Murthy GS, Hamadani M, Michaelis LC, et al Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in
relapsed/refractory acute myeloid leukemia.
Leukemia. 2025 Feb 15. doi: 10.1038/s41375-025-02528. PubMedAbstract available
OKABE S, Arai Y, Gotoh A Correspondence to: "Combination therapies with ponatinib and asciminib in a
preclinical model of chronic myeloid leukemia blast crisis with compound
mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521. PubMed
SU Y, Han Z, Ji Y, Liu A, et al Patterns and variations of copy number alterations in acute myeloid leukemia:
insights from the LeukAtlas database.
Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514. PubMedAbstract available
FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al Functions of the native NPM1 protein and its leukemic mutant.
Leukemia. 2025;39:276-290. PubMedAbstract available
YANG S, Zhang X, Gale RP, Huang X, et al Is there really an accelerated phase of chronic myeloid leukaemia at
presentation?
Leukemia. 2025;39:391-399. PubMedAbstract available
CALVO J, Naguibneva I, Kypraios A, Gilain F, et al High CD44 expression and enhanced E-selectin binding identified as biomarkers of
chemoresistant leukemic cells in human T-ALL.
Leukemia. 2025;39:323-336. PubMedAbstract available
ORTI G, Peczynski C, Boreland W, O'Reilly M, et al Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell
therapy following allogeneic hematopoietic cell transplantation: a transplant
complications and paediatric diseases working parties joint EBMT study.
Leukemia. 2025;39:431-437. PubMedAbstract available
January 2025
ABLE M, Kasper MA, Vick B, Schwach J, et al Effective eradication of acute myeloid leukemia stem cells with FLT3-directed
antibody-drug conjugates.
Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02510. PubMedAbstract available
LIU J, Kharazmi E, Liang Q, Chen Y, et al Maternal weight during pregnancy and risk of childhood acute lymphoblastic
leukemia in offspring.
Leukemia. 2025 Jan 26. doi: 10.1038/s41375-025-02517. PubMedAbstract available
TREMBLAY CS, Saw J, Yan F, Boyle JA, et al Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in
early T-cell precursor acute lymphoblastic leukemia.
Leukemia. 2025 Jan 23. doi: 10.1038/s41375-024-02491. PubMedAbstract available
LAUWEREINS L, Van Thillo Q, Demeyer S, Mentens N, et al TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute
lymphoblastic leukemia.
Leukemia. 2025 Jan 21. doi: 10.1038/s41375-025-02513. PubMedAbstract available
ADDINSELL HM, Cant R, Hull NJ, Wang YH, et al Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals
metabolic and immune dysregulation leading to altered macrophage polarization.
Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02511. PubMed
ANABTAWI N, Nicolet D, Alotaibi N, Buelow DR, et al Prognostic, biological, and structural implications of FLT3-JMD point mutations
in acute myeloid leukemia: an analysis of Alliance studies.
Leukemia. 2025 Jan 13. doi: 10.1038/s41375-024-02498. PubMedAbstract available
SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al A novel prognostic risk model for patients with refractory/relapsed acute myeloid
leukemia receiving venetoclax plus hypomethylating agents.
Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501. PubMedAbstract available
SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX
activation.
Leukemia. 2025;39:75-86. PubMedAbstract available
STRULLU M, Caye-Eude A, Robert E, Renard JM, et al CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class
kinase fusions in pediatric BCP-ALL.
Leukemia. 2025;39:64-74. PubMedAbstract available
JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al Monitoring clonal burden as an alternative to blast count for myelodysplastic
neoplasm treatment response.
Leukemia. 2025;39:166-177. PubMedAbstract available
LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
Leukemia. 2025;39:87-97. PubMedAbstract available
December 2024
SHI Z, Li J, Ding J, Zhang Y, et al ADAR1 is required for acute myeloid leukemia cell survival by modulating
post-transcriptional Wnt signaling through impairing miRNA biogenesis.
Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500. PubMedAbstract available
NABKI J, Al Deeban B, Sium AM, Cosentino C, et al Immunoglobulin light chain mutational status refines IGHV prognostic value in
identifying chronic lymphocytic leukemia patients with early treatment
requirement.
Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499. PubMedAbstract available
BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al Co-targeting of the thymic stromal lymphopoietin receptor to decrease
immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute
lymphoblastic leukemia.
Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493. PubMedAbstract available
ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al Relationship between donor source, pre-transplant measurable residual disease,
and outcome after allografting for adults with acute myeloid leukemia.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497. PubMedAbstract available
GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of
transcription factor TCF4.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470. PubMed
SHIMA H, Tono C, Tanizawa A, Ito M, et al Growth retardation and adult height in pediatric patients with chronic-phase
chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488. PubMed
ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al Prognostic relevance of treatment deviations in children with relapsed acute
lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474. PubMedAbstract available
MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al Allogeneic hematopoietic stem cell transplantation in adult acute myeloid
leukemia with t(16;21)(p11;q22)/FUS::ERG.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495. PubMed
HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al Incidence of Richter transformation of chronic lymphocytic leukemia/small
lymphocytic lymphoma in the targeted therapy era.
Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492. PubMed
ARZA-APALATEGI S, Heuts BMH, Bergevoet SM, Meering R, et al HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute
myelomonocytic leukemia.
Leukemia. 2024 Dec 4. doi: 10.1038/s41375-024-02485. PubMedAbstract available
SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study
comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus
chlorambucil in treatment-naive chronic lymphocytic leukemia.
Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487. PubMed
WALTER W, Nadarajah N, Hutter S, Muller H, et al Characterization of myeloproliferative neoplasms based on genetics only and
prognostication of transformation to blast phase.
Leukemia. 2024;38:2644-2652. PubMedAbstract available
HALILOVIC M, Abdelsalam M, Zabkiewicz J, Lazenby M, et al Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent
depletion of heat shock proteins.
Leukemia. 2024;38:2561-2572. PubMedAbstract available
November 2024
LOU J, Zhang Y, Tao J, Jin W, et al Infection-related pathway activation and vulnerability to arsenic trioxide in
acute promyelocytic leukemia with TTMV::RARA.
Leukemia. 2024 Nov 28. doi: 10.1038/s41375-024-02481. PubMed
HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid
leukemia via VEGF signaling.
Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471. PubMedAbstract available
KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al Clonal hematopoiesis in large granular lymphocytic leukemia.
Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460. PubMedAbstract available
DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452. PubMedAbstract available
KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia
by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454. PubMedAbstract available
SHAO Q, Wykretowicz J, Hu N, Bedi K, et al Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates
disease progression in chronic lymphocytic leukemia.
Leukemia. 2024 Nov 13. doi: 10.1038/s41375-024-02472. PubMed
TREMBLAY D, Csizmar C, DiNardo CD, Ball S, et al Venetoclax in combination with hypomethylating agents in chronic myelomonocytic
leukemia: a propensity score matched multicenter cohort study.
Leukemia. 2024 Nov 12. doi: 10.1038/s41375-024-02466. PubMed
BOUEYA IL, Sandhow L, Albuquerque JRP, Znaidi R, et al Endothelial heterogeneity in bone marrow: insights across development, adult life
and leukemia.
Leukemia. 2024 Nov 11. doi: 10.1038/s41375-024-02453. PubMedAbstract available
LI X, Zheng M, Ma S, Nie F, et al YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by
attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02451. PubMedAbstract available
EL CHAER F, Perissinotti AJ, Loghavi S, Zeidan AM, et al Pre-emptive therapeutic decisions based on measurable residual disease status in
acute myeloid leukemia: ready for prime time?
Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02458. PubMedAbstract available
SHAO X, Yokomori R, Ong JZL, Shen H, et al Transcriptional regulatory program controlled by MYB in T-cell acute
lymphoblastic leukemia.
Leukemia. 2024 Nov 2. doi: 10.1038/s41375-024-02455. PubMedAbstract available
INNES AJ, Hayden C, Orovboni V, Claudiani S, et al Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Leukemia. 2024;38:2443-2455. PubMedAbstract available
October 2024
SHIMONI A, Peczynski C, Labopin M, Kulagin A, et al Post-transplant cyclophosphamide separates graft-versus host disease and graft
versus leukemia effects after HLA-matched stem-cell transplantation for acute
myeloid leukemia.
Leukemia. 2024 Oct 31. doi: 10.1038/s41375-024-02445. PubMedAbstract available
SAFA-TAHAR-HENNI S, Paez Martinez K, Gress V, Esparza N, et al Comparative small molecule screening of primary human acute leukemias, engineered
human leukemia and leukemia cell lines.
Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400. PubMedAbstract available
SHAO Q, Wykretowicz J, Hu N, Bedi K, et al Aberrant BCAT1 expression augments MTOR activity and accelerates disease
progression in chronic lymphocytic leukemia.
Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448. PubMedAbstract available
NARDI F, Del Prete R, Drago R, Di Rita A, et al Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic
lymphocytic leukemia.
Leukemia. 2024 Oct 23. doi: 10.1038/s41375-024-02442. PubMedAbstract available
YU M, Nah GSS, Krishnan V, Sulaimi FNB, et al The BIM deletion polymorphism potentiates the survival of leukemia stem and
progenitor cells and impairs response to targeted therapies.
Leukemia. 2024 Oct 22. doi: 10.1038/s41375-024-02418. PubMedAbstract available
YANG C, Hu Y, Gao L, Li Z, et al Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a
potential therapy for high-PDE3A acute myeloid leukemia.
Leukemia. 2024 Oct 15. doi: 10.1038/s41375-024-02437. PubMedAbstract available
TETTERO JM, Cloos J, Bullinger L Acute myeloid leukemia: does sex matter?
Leukemia. 2024 Oct 14. doi: 10.1038/s41375-024-02435. PubMed
YAMAMOTO Y, Iba S, Inaguma Y, Okamoto A, et al ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
Leukemia. 2024 Oct 8. doi: 10.1038/s41375-024-02434. PubMed
SUNAMI Y, Yoshino S, Yamazaki Y, Iwamoto T, et al Rapid increase of C/EBPalpha p42 induces growth arrest of acute myeloid leukemia
(AML) cells by Cop1 deletion in Trib1-expressing AML.
Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02430. PubMedAbstract available
ZHANG N, Wen D, Wang T, Deng J, et al Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia
across countries with different incomes.
Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02433. PubMed
GODA C, Kulkarni R, Bustos Y, Li W, et al Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
Leukemia. 2024 Oct 2. doi: 10.1038/s41375-024-02415. PubMedAbstract available
KAZERANI M, Marcinek A, Philipp N, Brauchle B, et al Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell
engager-mediated function of bone marrow T cells at remission compared to initial
diagnosis and relapse.
Leukemia. 2024;38:2270-2275. PubMed
LEE YJ, Lee SY, Kim S, Kim SH, et al REXO5 promotes genomic integrity through regulating R-loop using its exonuclease
activity.
Leukemia. 2024;38:2150-2161. PubMedAbstract available
GALE RP, Jiang Q, Apperley JF, Hochhaus A, et al Is there really an accelerated phase of chronic myeloid leukaemia?
Leukemia. 2024;38:2085-2086. PubMed
September 2024
PATEL SA Managing the unmanageable: evidence-driven approaches to real-world patient
prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
Leukemia. 2024 Sep 30. doi: 10.1038/s41375-024-02417. PubMedAbstract available
SAKAMOTO KM Can PROTACs cure Leukemia?
Leukemia. 2024 Sep 26. doi: 10.1038/s41375-024-02427. PubMed
RAVANDI F, Senapati J, Jain N, Short NJ, et al Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD,
nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic
leukemia and lymphoma.
Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414. PubMedAbstract available
HUELSE JM, Bhasin SS, Jacobsen KM, Yim J, et al MERTK inhibition selectively activates a DC - T-cell axis to provide
anti-leukemia immunity.
Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02408. PubMedAbstract available
VOLTA L, Myburgh R, Pellegrino C, Koch C, et al Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with
CAR T-cells.
Leukemia. 2024 Sep 18. doi: 10.1038/s41375-024-02409. PubMedAbstract available
CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and
outcome of 87 patients reported to the European LeukemiaNet international
registry.
Leukemia. 2024 Sep 17. doi: 10.1038/s41375-024-02412. PubMed
ZHANG W, Yamamoto K, Chang YH, Yabushita T, et al HDAC7 is a potential therapeutic target in acute erythroid leukemia.
Leukemia. 2024 Sep 15. doi: 10.1038/s41375-024-02394. PubMedAbstract available
LIU B, Zhang X, Zhou Y, Liu H, et al USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem
cell regeneration and leukemia progression.
Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02338. PubMedAbstract available
RABIAN F, Chevret S, Gruson B, Thepot S, et al Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A
Groupe Francophone des Myelodysplasies (GFM) study.
Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02402. PubMed
KORBECKI J, Bosiacki M, Kupnicka P, Barczak K, et al CXCR4 as a therapeutic target in acute myeloid leukemia.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02326. PubMedAbstract available
HAGERSTRAND D, Oder B, Cortese D, Qu Y, et al The non-canonical BAF chromatin remodeling complex is a novel target of
spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02379. PubMedAbstract available
RHEINGOLD SR, Bhojwani D, Ji L, Xu X, et al Determinants of survival after first relapse of acute lymphoblastic leukemia: a
Children's Oncology Group study.
Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02395. PubMedAbstract available
STUTTERHEIM J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, et al Are measurable residual disease results after consolidation therapy useful in
children with acute lymphoblastic leukemia?
Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386. PubMedAbstract available
LIU T, Xu K, Pardeshi A, Myint SS, et al Early-life tobacco exposure is causally implicated in aberrant RAG-mediated
recombination in childhood acute lymphoblastic leukemia.
Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02407. PubMed
BOUCHER A, Murray J, Rao S Cohesin mutations in acute myeloid leukemia.
Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02406. PubMedAbstract available
WANG J, Jiang B, Li J, Liu L, et al Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian
patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382. PubMedAbstract available
VAN DER HAM CG, Suurenbroek LC, Kleisman MM, Antic Z, et al Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic
leukemia.
Leukemia. 2024 Sep 4. doi: 10.1038/s41375-024-02403. PubMedAbstract available
JABBOUR E, Apperley J, Cortes J, Rea D, et al Correction: Dose modification dynamics of ponatinib in patients with
chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02385. PubMed
TOMA MM, Skorski T Star wars against leukemia: attacking the clones.
Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369. PubMedAbstract available
CRUZ-RODRIGUEZ N, Tang H, Bateman B, Tang W, et al BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the
treatment of Ph(+) leukemias?
Leukemia. 2024;38:1885-1893. PubMedAbstract available
LEYTE-VIDAL A, DeFilippis R, Outhwaite IR, Kwan I, et al Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the
autoinhibited kinase conformation and confers resistance to asciminib.
Leukemia. 2024;38:2046-2050. PubMed
PIEMONTESE S, Labopin M, Choi G, Broers AEC, et al Older MRD vs. younger MUD in patients older than 50 years with AML in remission
using post-transplant cyclophosphamide.
Leukemia. 2024;38:2016-2022. PubMedAbstract available
JANN JC, Hergott CB, Winkler M, Liu Y, et al Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct
ontogeny and outcomes.
Leukemia. 2024;38:1992-2002. PubMedAbstract available
WANG J, Zhang Y, Li L, Wang L, et al Nudt15-mediated inflammatory signaling contributes to divergent outcomes in
leukemogenesis and hematopoiesis.
Leukemia. 2024;38:1958-1970. PubMedAbstract available
KEWAN T, Bahaj WS, Gurnari C, Ogbue OD, et al Clinical and molecular characteristics of extramedullary acute myeloid leukemias.
Leukemia. 2024;38:2032-2036. PubMed
AL AMRI R, Baloda V, Monaghan SA, Rosado FG, et al Validation of independent prognostic significance of blast count in a large
cohort of MDS patients.
Leukemia. 2024;38:2064-2067. PubMed
SPERK A, Gabriel A, Koch D, Augsburger A, et al FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major
experimental pitfall in myeloid cells.
Leukemia. 2024;38:2027-2031. PubMed
JALNAPURKAR SS, Pawar AS, George SS, Antony C, et al PHF6 suppresses self-renewal of leukemic stem cells in AML.
Leukemia. 2024;38:1938-1948. PubMedAbstract available
MOORMAN AV, Enshaei A, Murdy D, Joy M, et al Integration of genetics and MRD to define low risk patients with B-cell precursor
acute lymphoblastic leukaemia with intermediate MRD levels at the end of
induction.
Leukemia. 2024;38:2023-2026. PubMed
HERNANDEZ-SANCHEZ A, Gonzalez T, Sobas M, Strang E, et al Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and
prognostic implications - a HARMONY study.
Leukemia. 2024;38:1929-1937. PubMedAbstract available
LESKE IB, Hantschel O The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Leukemia. 2024;38:2041-2045. PubMed
August 2024
DERIGS P, Schubert ML, Dreger P, Schmitt A, et al Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic
lymphocytic leukemia: a phase 1/2 study.
Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392. PubMedAbstract available
PASTORCZAK A, Urbanska Z, Styka B, Miarka-Walczyk K, et al Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell
acute lymphoblastic leukemia.
Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02370. PubMedAbstract available
DEMBITZ V, Lawson H, Burt R, Natani S, et al Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying
high levels of the de novo fatty acid biosynthesis and desaturation.
Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02390. PubMedAbstract available
KOEDIJK JB, van der Werf I, Penter L, Vermeulen MA, et al A multidimensional analysis reveals distinct immune phenotypes and the
composition of immune aggregates in pediatric acute myeloid leukemia.
Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02381. PubMedAbstract available
CUGLIEVAN B, Kantarjian H, Rubnitz JE, Cooper TM, et al Menin inhibitors in pediatric acute leukemia: a comprehensive review and
recommendations to accelerate progress in collaboration with adult leukemia and
the international community.
Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02368. PubMedAbstract available
SUN Y, Wu Y, Pang G, Huang J, et al STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.
Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02383. PubMedAbstract available
RODRIGUEZ-ARBOLI E, Othus M, Freeman SD, Buccisano F, et al Optimal prognostic threshold for measurable residual disease positivity by
multiparameter flow cytometry in acute myeloid leukemia (AML).
Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02378. PubMed
BOUTZEN H, Murison A, Oriecuia A, Bansal S, et al Identification of leukemia stem cell subsets with distinct transcriptional,
epigenetic and functional properties.
Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02358. PubMedAbstract available
GAMBACORTI-PASSERINI C, Brummendorf TH, Abruzzese E, Kelly KR, et al Efficacy and safety of bosutinib in previously treated patients with chronic
myeloid leukemia: final results from the BYOND trial.
Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372. PubMedAbstract available
TISSINO E, Gaglio A, Nicolo A, Pozzo F, et al The VLA-4 integrin is constitutively active in circulating chronic lymphocytic
leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism
exploiting soluble blood-borne ligands.
Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376. PubMedAbstract available
ATAR D, Ruoff L, Mast AS, Krost S, et al Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents
antigen escape in acute myeloid leukemia.
Leukemia. 2024 Aug 3. doi: 10.1038/s41375-024-02351. PubMedAbstract available
CHATAIN N, Baumeister J, Szymanski de Toledo MA, Wong DWL, et al Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in
vivo by targeting malignant stem cells.
Leukemia. 2024;38:1825-1830. PubMedAbstract available
HOFERKOVA E, Seda V, Kadakova S, Verner J, et al Stromal cells engineered to express T cell factors induce robust CLL cell
proliferation in vitro and in PDX co-transplantations allowing the identification
of RAF inhibitors as anti-proliferative drugs.
Leukemia. 2024;38:1699-1711. PubMedAbstract available
BOUSQUETS-MUNOZ P, Molina O, Varela I, Alvarez-Eguiluz A, et al Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13)
infant AML.
Leukemia. 2024;38:1808-1812. PubMed
FONTANA D, Malighetti F, Villa M, Zambon A, et al Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
Leukemia. 2024;38:1843-1847. PubMed
FARHAT M, Croft W, Parry HM, Verma K, et al PD-1 expression contributes to functional impairment of NK cells in patients with
B-CLL.
Leukemia. 2024;38:1813-1817. PubMed
GALE RP, Phillips GL, Lazarus HM A modest proposal to the transplant publik to prevent harm to people with acute
myeloid leukaemia in 1st complete remission cured by chemotherapy.
Leukemia. 2024;38:1663-1666. PubMed
July 2024
WONG RL, Choi MY, Wang HY, Kipps TJ, et al Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader
therapy in chronic lymphocytic leukemia.
Leukemia. 2024 Jul 24. doi: 10.1038/s41375-024-02317. PubMedAbstract available
KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis
via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM
complex.
Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339. PubMed
ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al Molecular relapse after first-line intensive therapy in patients with CBF or
NPM1-mutated acute myeloid leukemia - a FILO study.
Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335. PubMedAbstract available
TERASAKI T, Semba Y, Sasaki K, Imanaga H, et al The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA
nuclear export in leukemia cells.
Leukemia. 2024 Jul 11. doi: 10.1038/s41375-024-02343. PubMedAbstract available
EFFICACE F, Mahon FX, Richter J, Piciocchi A, et al Health-related quality of life and symptoms of chronic myeloid leukemia patients
after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI
Trial.
Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341. PubMedAbstract available
OGBUE O, Kewan T, Bravo-Perez C, Unlu S, et al Hemolytic versus malproductive anemia in large granular lymphocytic leukemia.
Leukemia. 2024 Jul 9. doi: 10.1038/s41375-024-02323. PubMed
KIM H, Tan TK, Lee DZY, Huang XZ, et al Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute
lymphoblastic leukemia.
Leukemia. 2024 Jul 5. doi: 10.1038/s41375-024-02331. PubMedAbstract available
ERNST P, Rinke J, Franke GN, Dicker F, et al Treatment-free remission after third-line therapy with asciminib in chronic
myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
Leukemia. 2024 Jul 4. doi: 10.1038/s41375-024-02327. PubMed
DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic
leukemia identifies subtype-specific chromatin landscapes and gene regulatory
networks.
Leukemia. 2024 Jul 3. doi: 10.1038/s41375-024-02291. PubMed
YAMAMOTO Y, Watanabe T, Ureshino H, Kurahashi Y, et al DNA demethylating agents for chemoprevention of oncovirus-associated
leukemogenesis.
Leukemia. 2024;38:1613-1616. PubMed
SHAO Y, Kay NE, Gale RP, Liang Y, et al Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora
in chronic lymphocytic leukaemia.
Leukemia. 2024;38:1469-1473. PubMed
SCOTT S, Devonshire A, Dillon R, Thiede C, et al Recommendations from the AML molecular MRD expert advisory board.
Leukemia. 2024;38:1638-1641. PubMed
MASLAH N, Rety S, Bonnamy M, Aguinaga L, et al Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
Leukemia. 2024;38:1630-1633. PubMed
GROSS G, Alkadieri S, Meir A, Itzhaki O, et al Improved CAR-T cell activity associated with increased mitochondrial function
primed by galactose.
Leukemia. 2024;38:1534-1540. PubMedAbstract available
SHIMONY S, Garcia JS, Keating J, Chen EC, et al Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating
agents in newly diagnosed AML patients.
Leukemia. 2024;38:1494-1500. PubMedAbstract available
KOVECSES O, Mercier FE, McKeague M Nucleic acid therapeutics as differentiation agents for myeloid leukemias.
Leukemia. 2024;38:1441-1454. PubMedAbstract available
June 2024
YUN H, Zoller J, Zhou F, Rohde C, et al The landscape of RNA-chromatin interaction reveals small non-coding RNAs as
essential mediators of leukemia maintenance.
Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322. PubMedAbstract available
GALE RP, Hochhaus A Correction: To Mars and beyond. Space exploration and space medicine in Leukemia.
Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02324. PubMed
POZZO F, Forestieri G, Vit F, Ianna G, et al Early reappearance of intraclonal proliferative subpopulations in
ibrutinib-resistant chronic lymphocytic leukemia.
Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02301. PubMedAbstract available
YANAGIYA R, Miyatake Y, Watanabe N, Shimizu T, et al Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of
aggressive natural killer cell leukemia.
Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02296. PubMedAbstract available
PHILIPPE C, Jaud M, Feral K, Gay A, et al Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis
in acute myeloid leukemia apoptosis and response to chemotherapy.
Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02321. PubMedAbstract available
ABOU DALLE I, Moukalled N, El Cheikh J, Mohty M, et al Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently
asked questions.
Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02319. PubMedAbstract available
MCCARTHY N, Gui G, Dumezy F, Roumier C, et al Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow
cytometric measurable residual disease surveillance.
Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02300. PubMedAbstract available
MIAO H, Chen D, Ropa J, Purohit T, et al Combination of menin and kinase inhibitors as an effective treatment for leukemia
with NUP98 translocations.
Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02312. PubMedAbstract available
SALA-TORRA O, Beppu L, Wu Q, Welch E, et al Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in
chronic myeloid leukemia patients.
Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02285. PubMed
GREVER M, Andritsos L, Anghelina M, Arons E, et al Hairy cell leukemia variant and WHO classification correspondence Re: 5(th)
edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Leukemia. 2024 Jun 8. doi: 10.1038/s41375-024-02280. PubMed
OSTERGAARD A, Fiocco M, de Groot-Kruseman H, Moorman AV, et al ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Leukemia. 2024 Jun 6. doi: 10.1038/s41375-024-02287. PubMedAbstract available
ZHANG MY, Othus M, McMillen K, Erba HP, et al Association between class III obesity and overall survival in previously
untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02288. PubMedAbstract available
VAN DER VELDEN VHJ, Dombrink I, Alten J, Cazzaniga G, et al Analysis of measurable residual disease by IG/TR gene rearrangements: quality
assurance and updated EuroMRD guidelines.
Leukemia. 2024;38:1315-1322. PubMedAbstract available
SAYITOGLU EC, Luca BA, Boss AP, Thomas BC, et al AML/T cell interactomics uncover correlates of patient outcomes and the key role
of ICAM1 in T cell killing of AML.
Leukemia. 2024;38:1246-1255. PubMedAbstract available
YANG M, Ma Z, Wang C, Agca MC, et al Cre recombinase promotes leukemogenesis in the presence of both homozygous and
heterozygous FLT3-ITD.
Leukemia. 2024;38:1437-1439. PubMed
LU W, Lyu H, Xiao X, Bai X, et al Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in
high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
Leukemia. 2024;38:1419-1422. PubMed
VAN SPRONSEN MF, Van Gassen S, Duetz C, Westers TM, et al Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable
subtypes by computational clustering of haematopoietic stem and progenitor cells.
Leukemia. 2024;38:1365-1377. PubMedAbstract available
PERZOLLI A, Koedijk JB, Zwaan CM, Heidenreich O, et al Targeting the innate immune system in pediatric and adult AML.
Leukemia. 2024;38:1191-1201. PubMedAbstract available
May 2024
ZHU R, Shirley CM, Chu SH, Li L, et al Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3
tyrosine kinase inhibition.
Leukemia. 2024 May 29. doi: 10.1038/s41375-024-02292. PubMedAbstract available
GALE RP, Hochhaus A To Mars and beyond. Space exploration and space medicine in Leukemia.
Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286. PubMed
RUJKIJYANONT P, Inaba H Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in
low- and middle-income countries.
Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277. PubMedAbstract available
CORTES JE, Sasaki K, Kim DW, Hughes TP, et al Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia
with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year
follow-up results.
Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278. PubMedAbstract available
MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al ERIC recommendations for TP53 mutation analysis in chronic lymphocytic
leukemia-2024 update.
Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267. PubMedAbstract available
NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated
according to pediatric-based GMALL protocols.
Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264. PubMedAbstract available
KARAMI A, Skorski T DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid
leukemia patients.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269. PubMed
AWADA H, Durmaz A, Kewan T, Ullah F, et al Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute
myeloid leukemia: a multi-omics analysis.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268. PubMed
MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al TIF1beta activates leukemic transcriptional program in HSCs and promotes
BCR::ABL1-induced myeloid leukemia.
Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276. PubMedAbstract available
O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL
chemotolerance.
Leukemia. 2024;38:951-962. PubMedAbstract available
SRINIVASAN S, Keerthivasagam S Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric
ALL - AALL0232 trial insights.
Leukemia. 2024;38:1187-1188. PubMed
SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al CD22 CAR T cells demonstrate high response rates and safety in pediatric and
adult B-ALL: Phase 1b results.
Leukemia. 2024;38:963-968. PubMedAbstract available
WONG JC, Weinfurtner KM, Westover T, Kim J, et al 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in
myeloid malignancies.
Leukemia. 2024;38:1182-1186. PubMedAbstract available
YI W, Zhang J, Huang Y, Zhan Q, et al Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of
hematopoietic stem cells and leukemic stem cells.
Leukemia. 2024;38:1003-1018. PubMedAbstract available
April 2024
GUO J, Buettner R, Du L, Li Z, et al 8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the
methionine-MAT2A-SAM axis in acute myeloid leukemia.
Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222. PubMedAbstract available
IYODA S, Yoshida K, Shoji K, Ito N, et al KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute
myeloid leukemia.
Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244. PubMed
NORONHA N, Durette C, Cahuzac M, E Silva B, et al Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine
in acute myeloid leukemia.
Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250. PubMedAbstract available
CURIK N, Laznicka A, Polivkova V, Krizkova J, et al Combination therapies with ponatinib and asciminib in a preclinical model of
chronic myeloid leukemia blast crisis with compound mutations.
Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248. PubMed
MATSUI S, Ri C, Bolanos LC, Choi K, et al Metabolic reprogramming regulated by TRAF6 contributes to the leukemia
progression.
Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245. PubMedAbstract available
BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic
strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241. PubMedAbstract available
FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246. PubMedAbstract available
BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236. PubMedAbstract available
MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al Allogeneic haematopoietic cell transplantation for advanced systemic
mastocytosis: Best practice recommendations on behalf of the EBMT Practice
Harmonisation and Guidelines Committee.
Leukemia. 2024;38:699-711. PubMedAbstract available
LUBKE J, Christen D, Schwaab J, Kaiser A, et al Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis:
A retrospective analysis of the DRST and GREM registries.
Leukemia. 2024;38:810-821. PubMedAbstract available
SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al Hypomethylating agents plus venetoclax compared with intensive induction
chemotherapy regimens in molecularly defined secondary AML.
Leukemia. 2024;38:762-768. PubMedAbstract available
SEBERT M, Freiman L, Chaffaut C, Guerci A, et al Clinical impact of genetic alterations including germline DDX41 mutations in
MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia. 2024;38:918-922. PubMed
SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel
clusters and divergent ex-vivo drug responses.
Leukemia. 2024;38:751-761. PubMedAbstract available
March 2024
JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al A complex interplay of intra- and extracellular factors regulates the outcome of
fetal- and adult-derived MLL-rearranged leukemia.
Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235. PubMedAbstract available
BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al Management and outcome of patients with chronic myeloid leukemia in blast phase
in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast
Phase Registry.
Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204. PubMedAbstract available
DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus
hypomethylating agents versus conventional chemotherapy.
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208. PubMedAbstract available
KANTARJIAN H, Branford S, Breccia M, Cortes J, et al Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1
tyrosine kinase inhibitors in chronic myeloid leukemia?
Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229. PubMed
BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al Measurable residual disease quantification in adult patients with
KMT2A-rearranged acute lymphoblastic leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209. PubMed
FARROKHI A, Atre T, Rever J, Fidanza M, et al The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic
leukemia.
Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221. PubMedAbstract available
BONATO A, Chakraborty S, Bomben R, Canarutto G, et al NFKBIE mutations are selected by the tumor microenvironment and contribute to
immune escape in chronic lymphocytic leukemia.
Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224. PubMedAbstract available
ZACKOVA D, Semerad L, Faber E, Klamova H, et al Why are not all eligible chronic myeloid leukemia patients willing to attempt
tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to
the TKI stopping trial HALF.
Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215. PubMed
SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al Mutation order in acute myeloid leukemia identifies uncommon patterns of
evolution and illuminates phenotypic heterogeneity.
Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211. PubMedAbstract available
AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in
acute myeloid leukemia.
Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202. PubMed
THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute
myeloid leukemia.
Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193. PubMedAbstract available
PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al Asparaginase completion among adults including older patients with acute
lymphoblastic leukemia treated with a modified DFCI protocol.
Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201. PubMed
MA J, Liu YC, Voss RK, Ma J, et al Genomic and global gene expression profiling in pediatric and young adult acute
leukemia with PICALM::MLLT10 Fusion.
Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194. PubMedAbstract available
CHEN CC, Silberman RE, Ma D, Perry JA, et al Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
Leukemia. 2024;38:521-529. PubMedAbstract available
SANZ-ORTEGA L, Andersson A, Carlsten M Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects
infused NK cells to the AML-perturbed bone marrow.
Leukemia. 2024;38:579-589. PubMedAbstract available
PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al Loss of thymocyte competition underlies the tumor suppressive functions of the
E2a transcription factor in T-ALL.
Leukemia. 2024;38:491-501. PubMedAbstract available
SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced
apoptosis in monosomy 5/del(5q) AML.
Leukemia. 2024;38:530-537. PubMedAbstract available
BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions
and EVI1 overexpression.
Leukemia. 2024;38:545-556. PubMedAbstract available
February 2024
CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for
chronic myeloid leukemia: managing intolerance and resistance.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187. PubMedAbstract available
YANG X, Liu J, Liu W, Wu H, et al circFAM193B interaction with PRMT6 regulates AML leukemia stem cells
chemoresistance through altering the oxidative metabolism and lipid peroxidation.
Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189. PubMedAbstract available
FLYGT H, Soderlund S, Richter J, Saussele S, et al Correction: Treatment-free remission after a second TKI discontinuation attempt
in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim
results from the DAstop2 trial.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184. PubMed
MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al Influence of co-mutational patterns in disease phenotype and clinical outcomes of
chronic myelomonocytic leukemia.
Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190. PubMed
JUNK SV, Forster A, Schmidt G, Zimmermann M, et al Germline variants in patients developing second malignant neoplasms after therapy
for pediatric acute lymphoblastic leukemia-a case-control study.
Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173. PubMed
CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87
patients reported to the European LeukemiaNet international registry.
Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183. PubMedAbstract available
OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic
hematopoietic cell transplantation for acute myeloid leukemia.
Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172. PubMedAbstract available
AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al Comparison of karyotype scoring guidelines for evaluating karyotype complexity in
chronic lymphocytic leukemia.
Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177. PubMed
CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al Updates of the ERIC recommendations on how to report the results from
immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163. PubMed
LIN S, Schneider C, Su AH, Alexe G, et al The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response
to venetoclax in acute myeloid leukemia.
Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178. PubMed
DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute
Lymphoblastic Leukemia: A Children's Oncology Group Report.
Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166. PubMedAbstract available
LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al LIN28B promotes differentiation of fully transformed AML cells but is dispensable
for fetal leukemia suppression.
Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167. PubMed
FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al State-transition modeling of blood transcriptome predicts disease evolution and
treatment response in chronic myeloid leukemia.
Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142. PubMedAbstract available
KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC)
associated phenotype in AML patients undergoing allogeneic stem cell
transplantation in CR.
Leukemia. 2024;38:386-388. PubMed
ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell
self-renewal and disrupt early lymphopoiesis.
Leukemia. 2024;38:455-459. PubMed
GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al Prognostic impact of CEBPA mutational subgroups in adult AML.
Leukemia. 2024;38:281-290. PubMedAbstract available
HEHLMANN R, Lauseker M How to individualize therapy after failing milestones in chronic myeloid
leukaemia: weighting late response and early death from CML against risk of
alternative therapies.
Leukemia. 2024;38:465-466. PubMed
CHEN J, Gale RP Response to Pfirrmann et al.'s comment on How should we interpret conclusions of
TKI-stopping studies.
Leukemia. 2024;38:463-464. PubMed
LEE KH, Lee S, Park YH, Mun YC, et al Interleukin-15 and -21-activated, donor-derived NK cell infusion after
haploidentical HCT in high-risk AML and MDS-a cohort analysis.
Leukemia. 2024;38:451-454. PubMed
MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al Development of osteonecrosis and improved survival in B-ALL: results of
Children's Oncology Group Trial AALL0232.
Leukemia. 2024;38:258-265. PubMedAbstract available
CHEN Y, Wen J, Li Q, Peng D, et al RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence
and crosstalk with the microenvironment.
Leukemia. 2024;38:266-280. PubMedAbstract available
SUI P, Ge G, Chen S, Bai J, et al SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate
leukemogenesis.
Leukemia. 2024;38:408-411. PubMed
January 2024
DAM M, Centanni M, Friberg LE, Centanni D, et al Increase in peg-asparaginase clearance as a predictor for inactivation in
patients with acute lymphoblastic leukemia.
Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153. PubMedAbstract available
JABBOUR E, Apperley J, Cortes J, Rea D, et al Dose modification dynamics of ponatinib in patients with chronic-phase chronic
myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159. PubMedAbstract available
FLYGT H, Soderlund S, Richter J, Saussele S, et al Treatment-free remission after a second TKI discontinuation attempt in patients
with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from
the DAstop2 trial.
Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145. PubMedAbstract available
TAN SH, Tan TK, Yokomori R, Liao M, et al Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and
dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125. PubMed
TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al Impact of hemodilution on flow cytometry based measurable residual disease
assessment in acute myeloid leukemia.
Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158. PubMedAbstract available
APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al Clinical evaluation of complete remission (CR) with partial hematologic recovery
(CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143. PubMed
KANG H, Hoang DH, Valerio M, Pathak K, et al OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent
ribogenesis in acute myeloid leukemia.
Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146. PubMed
TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al Clonal medicine targeting DNA damage response eradicates leukemia.
Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138. PubMed
CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in
the acute myeloid leukemia niche.
Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136. PubMedAbstract available
HANEL G, Schonle A, Neumann AS, Nixdorf D, et al Combining venetoclax and azacytidine with T-cell bispecific antibodies for
treatment of acute myeloid leukemia: a preclinical assessment.
Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127. PubMed
VALTIS YK, Flamand Y, Shimony S, Place AE, et al Treatment completion, asparaginase completion, and oncologic outcomes among
children, adolescents and young adults with acute lymphoblastic leukemia treated
with DFCI Consortium Protocols.
Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115. PubMedAbstract available
SUNG PJ, Selvam M, Riedel SS, Xie HM, et al FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in
acute myeloid leukemia.
Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131. PubMedAbstract available
POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of
FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118. PubMed
MORLEY AA Quantifying measurable residual disease correctly.
Leukemia. 2024;38:221-222. PubMed
TYAGI A, Jaggupilli A, Ly S, Yuan B, et al TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML
growth synergistically with venetoclax.
Leukemia. 2024;38:82-95. PubMedAbstract available
ZHOU YL, Zhao MY, Gale RP, Jiang H, et al Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in
adults with acute myeloid leukaemia with normal cytogenetics.
Leukemia. 2024;38:223-225. PubMed
CHEN J Response to comment on Have we been qualifying measurable residual disease
correctly?
Leukemia. 2024;38:219-220. PubMed
RADIVOYEVITCH T, Gale RP, Kalaycio ME What do atomic bomb survivors teach us about therapy-free remission in people
with chronic myeloid leukaemia?
Leukemia. 2024;38:207-209. PubMed
GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al A randomized phase III study of standard versus high-dose cytarabine with or
without vorinostat for AML.
Leukemia. 2024;38:58-66. PubMedAbstract available
YAN M, Liu M, Davis AG, Stoner SA, et al Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model
reveals regulatory networks promoting leukemic transformation.
Leukemia. 2024;38:31-44. PubMedAbstract available
December 2023
AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid
leukemia.
Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117. PubMedAbstract available
YANADA M, Yamasaki S, Kondo T, Kawata T, et al Allogeneic hematopoietic cell transplantation for patients with acute myeloid
leukemia not in remission.
Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119. PubMedAbstract available
MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has
prognostic value for treatment-free remission in chronic myeloid leukemia
patients treated with imatinib.
Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109. PubMedAbstract available
DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al Backtracking to the future: unraveling the origins of childhood leukemia.
Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111. PubMed
FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al Correction: A positive feedback loop regulation between NOTCH1 and USP11 in
T-cell leukemia.
Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112. PubMed
MURPHY T, Mason JM, Leber B, Bray MR, et al Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase
4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and
higher-risk myelodysplastic neoplasms.
Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110. PubMedAbstract available
HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid
leukemia.
Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102. PubMedAbstract available
KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid
leukemia.
Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104. PubMed
TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic
reprogramming and survival in chronic lymphocytic leukemia.
Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103. PubMedAbstract available
SABA L, Landau KS, Liang H, Fu CL, et al Real world analysis on the determinants of survival in primary plasma cell
leukemia in the United States.
Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100. PubMed
ANTIC Z, van Bommel A, Riege K, Lentes J, et al Recurrent DNMT3B rearrangements are associated with unfavorable outcome in
dicentric (9;20)-positive pediatric BCP-ALL.
Leukemia. 2023;37:2522-2525. PubMed
SCHIFFER CA Glasdigib fails to slay the hedgehog in pivotal AML trials.
Leukemia. 2023;37:2520-2521. PubMed
BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al Evaluation of complete response to azacitidine according to the revised
International Working Group 2023 response criteria for higher risk MDS. Does it
make a difference in patients' outcome?
Leukemia. 2023;37:2517-2519. PubMed
XIANG J, Devenport JM, Carter AJ, Staser KW, et al An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
Leukemia. 2023;37:2448-2456. PubMedAbstract available
November 2023
MILIARA S, Cozzi E, Zhong X, Chan I, et al The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute
myeloid leukemia.
Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098. PubMed
PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal
evolution to Richter transformation.
Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095. PubMedAbstract available
OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al Sex-associated differences in frequencies and prognostic impact of recurrent
genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068. PubMedAbstract available
ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al Impact of age and comorbidities on the efficacy and tolerability of bosutinib in
previously treated patients with chronic myeloid leukemia: results from the phase
4 BYOND study.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080. PubMedAbstract available
FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096. PubMed
LEUNG KT, Cai J, Liu Y, Chan KYY, et al Prognostic implications of CD9 in childhood acute lymphoblastic leukemia:
insights from a nationwide multicenter study in China.
Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089. PubMedAbstract available
ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al Genomic DNA-based measurable residual disease monitoring in pediatric acute
myeloid leukemia: unselected consecutive cohort study.
Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083. PubMedAbstract available
WALTER RB Perspective on measurable residual disease testing in acute myeloid leukemia.
Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084. PubMed
WU Y, Zehnle PMA, Rajak J, Koleci N, et al BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic
leukemia.
Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079. PubMedAbstract available
ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al PDP1 is a key metabolic gatekeeper and modulator of drug resistance in
FLT3-ITD-positive acute myeloid leukemia.
Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041. PubMedAbstract available
TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al High-dose cytarabine induction therapy and flow cytometric measurable residual
disease monitoring for children with acute myeloid leukemia.
Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075. PubMed
HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al Single-cell analysis of immune recognition in chronic myeloid leukemia patients
following tyrosine kinase inhibitor discontinuation.
Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074. PubMedAbstract available
WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al Markers of intestinal mucositis to predict blood stream infections at the onset
of fever during treatment for childhood acute leukemia.
Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077. PubMedAbstract available
FALINI B, Gjertsen BT, Andresen V The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant:
are they druggable in AML?
Leukemia. 2023;37:2173-2175. PubMed
LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al Survival with chronic myeloid leukaemia after failing milestones.
Leukemia. 2023;37:2231-2236. PubMedAbstract available
DU W, Xia Z, Luo Z, Chen Y, et al A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged
AML.
Leukemia. 2023;37:2286-2291. PubMed
BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al Ppm1d truncating mutations promote the development of genotoxic stress-induced
AML.
Leukemia. 2023;37:2209-2220. PubMedAbstract available
FENG Y, Qi S, Liu X, Zhang L, et al Have we been qualifying measurable residual disease correctly?
Leukemia. 2023;37:2168-2172. PubMed
LI S, Wang X, Liu L, Liu J, et al CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high
efficacy in the treatment of patients with relapsed and refractory T cell
malignancies.
Leukemia. 2023;37:2176-2186. PubMedAbstract available
October 2023
CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid
leukemia to cardiac glycosides.
Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076. PubMedAbstract available
BISCHOF L, Ussmann J, Grimm J, Bill M, et al Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid
leukemia patients after allogeneic hematopoietic stem cell transplantation.
Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072. PubMed
V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al Tisagenlecleucel vs. historical standard of care in children and young adult
patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042. PubMedAbstract available
WU A, Yen R, Grasedieck S, Lin H, et al Identification of multivariable microRNA and clinical biomarker panels to predict
imatinib response in chronic myeloid leukemia at diagnosis.
Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062. PubMedAbstract available
JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell
acute lymphoblastic leukemia.
Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057. PubMedAbstract available
DEL GIUDICE I, Foa R Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066. PubMed
ECKARDT JN, Stasik S, Rollig C, Petzold A, et al Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061. PubMedAbstract available
OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al Expression profiling of extramedullary acute myeloid leukemia suggests
involvement of epithelial-mesenchymal transition pathways.
Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054. PubMedAbstract available
KANTARJIAN HM What is the impact of failing to achieve TKI therapy milestones in chronic
myeloid leukemia.
Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053. PubMed
TULKENS D, Boelens M, Naert T, Carron M, et al Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia
in Xenopus tropicalis.
Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052. PubMedAbstract available
CROSS NCP, Ernst T, Branford S, Cayuela JM, et al European LeukemiaNet laboratory recommendations for the diagnosis and management
of chronic myeloid leukemia.
Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048. PubMedAbstract available
JAHN E, Saadati M, Fenaux P, Gobbi M, et al Correction: Clinical impact of the genomic landscape and leukemogenic
trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017. PubMed
HUBER S, Baer C, Hutter S, Dicker F, et al Risk assessment according to IPSS-M is superior to AML ELN risk classification in
MDS/AML overlap patients defined by ICC.
Leukemia. 2023;37:2138-2141. PubMed
OTHMAN J, Potter N, Mokretar K, Taussig D, et al FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3
mutated AML.
Leukemia. 2023;37:2066-2072. PubMedAbstract available
FISHER JG, Doyle ADP, Graham LV, Sonar S, et al XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and
overcomes HLA-E expression.
Leukemia. 2023;37:2036-2049. PubMedAbstract available
CASERTA C, Nucera S, Barcella M, Fazio G, et al miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that
correlates with minimal residual disease.
Leukemia. 2023;37:1994-2005. PubMedAbstract available
TIAN Z, Shi C, Yang G, Allen JK, et al Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that
targets CRLF2-rearranged Ph-like B-ALL.
Leukemia. 2023;37:2006-2016. PubMedAbstract available
GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects
by compromising neutrophil chemotaxis.
Leukemia. 2023;37:2115-2124. PubMedAbstract available
September 2023
MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al mTORC1-selective activation of translation elongation promotes disease
progression in chronic lymphocytic leukemia.
Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043. PubMedAbstract available
JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to
fludarabine in chronic lymphocytic leukemia.
Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035. PubMedAbstract available
FECHINA L, Popov A, Tsaur G, Henze G, et al Combination of chemotherapy and all-trans retinoic acid for the treatment
KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby
trial.
Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034. PubMed
KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al Efficacy and safety of bemcentinib in patients with advanced myelodysplastic
neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO
phase II BERGAMO trial.
Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029. PubMed
DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute
myeloid leukemia.
Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020. PubMedAbstract available
ECKARDT JN, Bill M, Rausch C, Metzeler K, et al Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid
leukemia - implications for the European leukemia net risk classification.
Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016. PubMed